Abstract
Background On December 31, 2019, an outbreak of 2019-nCoV in humans was reported in Wuhan, China. We analyzed data from field investigations and genetic sequencing to provide evidence and characteristics of human-to-human transmission.
Methods A confirmed case of 2019-nCoV was defined if a suspected case was verified with positive of 2019-nCoV in throat swabs, nasal swabs, bronchoalveolar lavage fluid (BALF), or endotracheal aspirates by real-time reverse transcriptase polymerase chain reaction assay (RT-PCR) or genetic sequencing. Field investigations were conducted for each confirmed case. Clinical and demographic data of the confirmed cases were collected from their medical records. Exposure and travel history were obtained by interviewing confirmed cases.
Results A total of 188 confirmed cases were identified from January 1 to 27, 2020 in Guangdong Province, China. Of them, 84 (44.6%) cases were from 31 cluster infections. Thirty cases (16.0%) were identified as secondary cases, in which 25 and 9 cases were identified in cluster infections and family cluster infections, respectively. 2019-nCoV were detected in three cases with mild respiratory symptoms, and in two asymptomatic cases. The whole viral genomes within the same family cluster infections were exactly the same, and presented a few unique single nucleotide variants (SNVs) compared with 2019-nCoVs identified in Wuhan on December 2019.
Conclusions We observed increasing human-to-human transmissions of 2019-nCoV in Guangdong, China, and most of them were identified in cluster infections. Our findings indicate that prevention strategies of containing the person-to-person transmission of 2019-nCoV in households, hospitals and communities are urgently needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Key Research and Development Program of China (2018YFA0606200, 2018YFA0606202), the Science and Technology Program of Guangdong Province (2018B020207006, 2019B020208005, 2019B111103001), Guangzhou Science and technology Plan Project (201804010383).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.